Acquisitions - Acquired In-process Research and Development (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
Jun. 30, 2023	Dec. 31, 2023
Acquisitions
Asset acquisition, acquired in-process research and development expense		$ 1,095,449
VectivBio Holding AG and its subsidiaries
Acquisitions
Asset acquisition, acquired in-process research and development expense	$ 1,100,000

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

Name:	us-gaap_AssetAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration